18 terminated. 18 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Terminated 18 |
| Phase 2 | 1 | Terminated 1 |
Follow Mycoses: new trials by email Literature Review of Mycoses trials Research Report on Mycoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT) Dupilumab, Placebo, Intranasal Corticosteroid Sprays (INCS) - Allergic Fungal Rhinosinusitis | Phase 3 | Terminated | Emory University | 5 | 2023-10-26 | 2025-05-08 |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia | Phase 3 | Terminated | Scynexis, Inc. | 68 | 2022-08-03 | 2026-08-10 |
| Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study) PC945, Placebo - Refractory IPA | Phase 3 | Terminated | Pulmocide Ltd | 85 | 2022-06-14 | 2026-04-30 |
| Cryptococcal Antigen Screening Plus Sertraline Sertraline, Placebo Oral Tablet, Fluconazole - Cryptococcosis, Cryptococcal Infections | Phase 3 | Terminated | University of Minnesota | 22 | 2017-11-15 | 2020-06-09 |
| Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis micafungin, amphotericin B deoxycholate - Candidiasis | Phase 3 | Terminated | Astellas Pharma Global Development, Inc. | 30 | 2013-02-01 | 2015-11-04 |
| A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis Anidulafungin/Fluconazole - Candidemia | Phase 3 | Terminated | Pfizer | 17 | 2010-12-01 | 2015-10-28 |
| A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients voriconazole - Candidiasis | Phase 3 | Terminated | Pfizer | 23 | 2010-10-01 | 2016-06-23 |
| Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails NAB001, Vehicle alone - Onychomycosis | Phase 3 | Terminated | Promius Pharma, LLC | 468 | 2010-09-01 | 2013-07-11 |
| Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails NAB001, Placebo control - Onychomycosis | Phase 3 | Terminated | Promius Pharma, LLC | 458 | 2010-09-01 | 2013-07-11 |
| An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System Active Anidulafungin, Active Caspofungin - Fungemia, Neutropenia | Phase 3 | Terminated | Pfizer | 21 | 2009-08-01 | 2012-12-20 |
| An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida Active anidulafungin, Active Caspofungin - Candidiasis, Fungemia | Phase 3 | Terminated | Pfizer | 41 | 2009-04-01 | 2013-08-01 |
| An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot Placebo cream, Ketoconazole 2% cream (formulation F012) (Nizoral), Ketoconazole 2% cream (formulation F126) - Tinea Pedis | Phase 3 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 583 | 2007-07-01 | 2014-04-29 |
| DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) Pafuramidine maleate (DB289), Trimethoprim-Sulfamethoxazole (TMP-SMX) - Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia | Phase 3 | Terminated | Immtech Pharmaceuticals, Inc | 48 | 2006-05-01 | 2013-03-07 |
| Caspofungin Study for Fungal Infections in Adults in Critical Care Settings Caspofungin, Placebo - Candidiasis | Phase 3 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 1200 | 2004-10-01 | 2014-12-05 |
| Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV Isoniazid (INH), Trimethoprim/Sulfamethoxazole (TMP/SMX), Isoniazid Placebo (PL) - HIV Infection, Tuberculosis | Phase 2 / Phase 3 | Terminated | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 1354 | 2004-02-01 | 2019-02-05 |
| Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU Micafungin, Placebo - Invasive Fungal Infections | Phase 3 | Terminated | Astellas Pharma Inc | 104 | 2003-01-01 | 2012-03-27 |
| Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria daptomycin - Gram-Positive Bacterial Infections | Phase 3 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 75 | 2002-12-19 | 2017-06-14 |
| Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients Trimetrexate glucuronate, Methylprednisolone, Pentamidine isethionate - Pneumonia, Pneumocystis Carinii, HIV Infections | Phase 3 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 240 | 2021-11-03 |
Candidemia (5) · Candidiasis (5) · Candidiasis, Invasive (3) · HIV Infections (3) · Pneumonia, Pneumocystis (3) · Torulopsis (3) · AIDS-Related Opportunistic Infections (2) · Acquired Immunodeficiency Syndrome (2) · Fungemia (2) · Onychomycosis (2) · Allergic Fungal Sinusitis (1) · Bacteremia (1) · Bacterial Infections (1) · Cryptococcosis (1)
Bacterial Infections and Mycoses (18) · Infections (18) · Pathological Conditions, Signs and Symptoms (8) · Inflammation (6) · Invasive Fungal Infections (6) · Pathologic Processes (6) · Sepsis (6) · Systemic Inflammatory Response Syndrome (6) · Immune System Diseases (5) · Respiratory Tract Diseases (5) · Blood-Borne Infections (4) · Communicable Diseases (4) · Immunologic Deficiency Syndromes (4) · Lentivirus Infections (4)
Fluconazole (3) · Micafungin (3) · Trimethoprim, Sulfamethoxazole Drug Combination (3) · Anidulafungin (2) · Caspofungin (2) · Amphotericin B (1) · Daptomycin (1) · Echinocandins (1) · Injections (1) · Isoniazid (1) · Ketoconazole (1) · Leucovorin (1) · Methylprednisolone (1) · Pentamidine (1) · Sertraline (1)
Pfizer (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Promius Pharma, LLC (2) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Emory University (1) · Immtech Pharmaceuticals, Inc (1) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Pulmocide Ltd (1) · Scynexis, Inc. (1) · University of Minnesota (1)
United States (11) · Canada (5) · Belgium (3) · Bulgaria (3) · China (3) · France (3) · Greece (3) · Israel (3) · Italy (3) · Poland (3) · Brazil (2) · Colombia (2) · Germany (2) · Hungary (2) · Philippines (2)
Joanne Fraser, PhD (2) · Kent Allenby, MD (2) · Amanda Peppercorn, MD (1) · Carl Fichtenbaum, MD (1) · Charles D. Mitchell, MD (1) · David Angulo, MD (1) · Elizabeth K Nalintya, MBChB MPH (1) · George McSherry, MD (1) · Jose Vazquez, MD (1) · Joshua M Levy, MD, MPH, MSc (1) · Judith Aberg, MD (1) · Kathleen Mullane, DO (1)
PMID 28459966, PMID 28597967, PMID 33891293, PMID 18230259, PMID 20607114, PMID 21732834, PMID 26872154, PMID 27636722, PMID 29596222, PMID 31280481, PMID 32415846
2009 (1), U01AI068632 (1), U01AI125003 (1)